The principal action of testolactone is reported to be inhibition of
aromatase activity and the reduction in
estrogen synthesis that follows. Androstenedione, a 19-carbon
steroid hormone produced in the
adrenal glands and the
gonads, is where estrone synthesis originates and is the source of estrogen in
postmenopausal women.
In vitro studies report that the aromatase inhibition may be noncompetitive and irreversible, and could possibly account for the persistence of this drug's effect on estrogen synthesis after drug withdrawal. This reduction is substantially less than with second- and third-generation aromatase inhibitors. However, its
affinity for the AR is very low; in one study, it showed 0.0029% of the
affinity of the
anabolic steroid metribolone (100%) for the human AR (Ki = 41 μM and 1.18 nM, respectively). In accordance, androgenic side effects such as
hirsutism,
acne, and
voice changes have been reported in no women in clinical trials with testolactone. ==Chemistry==